E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Myelodysplastic syndrome (MDS) is a clonal disease of the bone marrow stem cells. The disease is frequent/asociated with cytopenia and/or blastosis. an evolution to an acute leukemia is not frequent (30%). Treatments are very disapointing especially for high risk MDS. The pronossis mainly depens on blastosis, cytopenia and cytogenetic abnormalities but the disease is typically uncurable ( expect BMT). |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate response to lenalidomide (according to IWG criteria) in adult MDS with deletion (del) 5q[31] cytogenetic abnormality and intermediate-2 or high-risk (International Prognostic Scoring System [IPSS]) MDS |
|
E.2.2 | Secondary objectives of the trial |
Evaluate duration of response, progression to AML, survival and safety of lenalidomide in subjects with intermediate-2-risk or high risk MDS associated with a del 5q [31]. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age ≥ 18 years at the time of signing the informed consent form 2. Must understand and voluntarily sign an informed consent form
3. Must be able to adhere to the study visit schedule and other protocol requirements 4. Concurrent corticosteroids used for medical conditions other than MDS allowed provided subject is on a stable or decreasing dose for ≥ 1 week prior to study entry 5. Prior thalidomide allowed 6. Documented diagnosis of MDS (RA, RARS, RAEB, RAEB-T and CMML with WBC < 13,000/mm3 according to FAB classification) that meets IPSS criteria for intermediate-2 or high-risk disease and has an associated del 5q[31] (the deleted chromosomal region must include 5q[31]), with or without additional cytogenetic abnormalities 7 Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test 10 – 14 days and again within 24 hours prior to starting study drug. In addition, sexually active WCBP must agree to continued abstinence from heterosexual intercourse or use 2 adequate contraceptive methods, started at least one month prior to onset of treatment, and continued during the whole study until the first menstruations that follow treatment discontinuation (See appendix for acceptable methods). WCBP must agree to have pregnancy tests weekly for the first 4 weeks, then every 4 weeks if menstruation is regular or every 2 weeks if menstruation is irregular,while on study drug. Negativity of the test should be checked before restarting treatment 8 Platelet count > 25,000u/L 9. Absolute Neutrophil count > 500u/L
(A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months).
|
|
E.4 | Principal exclusion criteria |
1. Pregnant or lactating females. 2. Prior therapy with lenalidomide 3. Proliferative (WBC ≥ 13,000/mL) chronic myelomonocytic leukemia (CMML) 4. Prior ≥ grade-2 NCI CTCAE (v 3.0) allergic reaction to thalidomide 5. Prior desquamating (blistering) rash while taking thalidomide 6. Prior history of malignancy other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for ≥ 3 years 7. Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days 8. Less than 6 months since prior allogeneic bone marrow transplantation 9. Less than 3 months since prior autologous bone marrow or stem cell transplantation 10. Recombinant human erythropoietin (rHuEPO) therapy received within 28 days 11. Use of androgens other than for treating hypogonadism 12. Known HIV-1 positivity 13. Any serious medical condition or psychiatric illness that will prevent the subject from signing the informed consent form or will place the subject at unacceptable risk if he or she participates in the study 14. Any of the following laboratory abnormalities: Serum creatinine > 2.0 mg/dL (177 mmol/L) Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 3.0 x upper limit of normal (ULN) Serum total bilirubin > 1.5 mg/dL,: 15. Subjects with ≥ grade-2 neuropathy 16. Clinically significant anemia due to iron, B12, or folate deficiencies, or autoimmune or hereditary hemolysis or gastrointestinal bleeding (the subject must have a marrow aspirate that is evaluable for storage iron)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary: i ncidence of significant hematological response, according to IWG criteria including CR, PR or, major HI, (HI-E, Hl-N,or Hl- P), and cytogenetic response. Secondary: Duration of responses ie :CR, PR, major HI, ( HI-E, HI-N,or HI-P),and cytogenetic response) from response achievement Time to progression to AML from inclusion Survival from inclusion Safety (type, frequency, and severity [National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0] of adverse events (AEs), and relationship of AEs to lenalidomide.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 17 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 12 |